ClinicalTrials.gg
Not yet recruitingNCT07943247MSUpdated Nov 17, 2026

Correlation Between Physical Activity and Pulmonary Endurance in MS Patients

An observational study in Multiple Sclerosis, sponsored by Cairo University. Not yet recruiting. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Cairo University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
94
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Multiple Sclerosis by Cairo University — 8 open to participants now, 10 under way, none of them phase 3. Multiple Sclerosis · Cairo University.

Started
2026
with 3 others
Observational
6 of 26
1 open now
Registered
26th of 26
by date

Among the 26 studies in Multiple Sclerosis by Cairo University, this one is one of 4 that started in 2026, is one of 6 observational ones, and was the 26th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

8 of the 26 studies in Multiple Sclerosis by Cairo University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Multiple Sclerosis by Cairo University, or all of them as a file.
02

Study summary

Multiple sclerosis (MS) is a chronic neurological disease that can affect movement, muscle strength, physical activity, and breathing. Individuals with MS may experience reduced physical activity and changes in pulmonary function, even during the early stages of the disease. However, the relationship between physical activity levels and pulmonary function in individuals with MS remains insufficiently understood. This observational study aims to investigate whether physical activity levels are associated with pulmonary function in adults with multiple sclerosis. A total of 94 participants with a confirmed diagnosis of MS are expected to be recruited. Physical activity will be assessed using the Arabic version of the International Physical Activity Questionnaire-Short Form (IPAQ-SF), while pulmonary function will be evaluated using spirometry. The study will examine whether individuals with different levels of physical activity also demonstrate differences in pulmonary function. The findings may help improve understanding of physical and respiratory health in individuals with MS and inform future rehabilitation assessment and management strategies.

Read the detailed description

Multiple sclerosis (MS) is a chronic immune-mediated inflammatory and neurodegenerative disorder of the central nervous system characterized by demyelination, axonal injury, and progressive neurological dysfunction. Individuals with MS may experience muscle weakness, fatigue, impaired mobility, reduced physical activity, and respiratory dysfunction. Reduced habitual physical activity may contribute to generalized physical deconditioning, whereas impaired pulmonary function may be associated with reduced exercise tolerance and limitations in daily physical activities. Although previous research has investigated physical activity and respiratory impairments in individuals with MS, evidence regarding the direct association between habitual physical activity and spirometric pulmonary function remains limited. Therefore, this study aims to investigate the correlation between physical activity and pulmonary function in individuals with multiple sclerosis.

This study will employ an observational, cross-sectional design involving a target sample of 94 adults with neurologist-confirmed multiple sclerosis recruited from neurology outpatient clinics and physical therapy departments in Egypt. Following eligibility screening and written informed consent, participants will undergo a single assessment session. Demographic and relevant clinical information will be collected, including disease characteristics, medication history, smoking status, and neurological disability assessed using the Expanded Disability Status Scale (EDSS). Habitual physical activity during the preceding seven days will be assessed using the Arabic version of the International Physical Activity Questionnaire-Short Form (IPAQ-SF), which provides estimates of physical activity expressed in metabolic equivalent minutes per week (MET-min/week). Pulmonary function will be assessed using a calibrated computerized spirometer following standardized American Thoracic Society/European Respiratory Society (ATS/ERS) procedures. The relationship between physical activity and pulmonary function will be investigated using correlation-based statistical analysis. The study will test the null hypothesis that no association exists between physical activity and pulmonary function in individuals with MS. As this is a cross-sectional observational study, the findings will be interpreted as associations rather than evidence of causation. No therapeutic intervention will be administered as part of the study. The results may contribute to a better understanding of the relationship between habitual physical activity and respiratory function in MS and provide information relevant to future rehabilitation research and clinical assessment.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with neurologist-confirmed MS will be screened for eligibility. The diagnosis, MS phenotype, disease duration, current disease-modifying therapy, recent relapse history, and relevant comorbidity will be verified from the medical record where available.

Eligibility criteria

**Inclusion Criteria:**

Are aged 20-40 years.

Are clinically stable at the time of assessment.

18-29.

Have experienced no acute MS relapse or systemic treatment during the preceding 30 days.

Mini-mental status score > 24.

Can understand and follow the assessment instructions.

Can perform acceptable spirometry maneuvers.

Can complete the physical activity questionnaire independently or with standardized clarification from the assessor.

Provide written .

**Exclusion Criteria:**

A diagnosed pulmonary disorder likely to affect spirometry independently, including , uncontrolled asthma, bronchiectasis, interstitial lung disease, or a history of major pulmonary surgery.

An acute respiratory tract infection during the preceding four weeks.

Unstable or cardiovascular disease that contraindicates maximal expiratory efforts or physical assessment.

A neurological disorder other than MS that may independently affect muscle strength, muscle quantity, physical activity, or pulmonary function.

A major musculoskeletal disorder, recent fracture, recent orthopedic surgery, or lower-limb injury that interferes with usual physical activity.

Pregnancy.

Cognitive, communication, or behavioral impairment that prevents valid completion of the assessment.

Any to spirometry according to ATS/ERS recommendations (Graham et al., 2019).

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
94 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Correlation Between Physical Activity and Forced Vital Capacity (FVC) in Individuals with Multiple Sclerosis

    The primary outcome will be the correlation between total self-reported physical activity and forced vital capacity (FVC) in individuals with multiple sclerosis. Physical activity will be assessed using the Arabic version of the International Physical Activity Questionnaire-Short Form (IPAQ-SF), with total physical activity expressed in metabolic equivalent minutes per week (MET-min/week). FVC will be measured in liters using standardized computerized spirometry according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. The association between total physical activity and FVC will be evaluated using correlation analysis.

    Time frame: At a single study visit (Day 1); physical activity will be assessed for the preceding 7 days.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
May 1, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07943247
Lead sponsor
Cairo University
Responsible party
Rana Alameldeen Mostafa Ali (teaching assistant, Cairo University) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Rana alm alameldeen, master
Contact
ranaalm98@yahoo.com
00201551787850

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion